千金药业(600479.SH)：子公司获得药品注册证书

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received the drug registration certificate for Lurasidone Hydrochloride Tablets from the National Medical Products Administration, marking a significant milestone for the company in the psychiatric medication market [1] Company Summary - Qianjin Xiangjiang Pharmaceutical, a subsidiary of Qianjin Pharmaceutical, has been approved for Lurasidone Hydrochloride Tablets, which are used to treat schizophrenia [1] - The cumulative R&D investment by Qianjin Xiangjiang Pharmaceutical in Lurasidone Hydrochloride Tablets amounts to RMB 6.3294 million [1] Industry Summary - Lurasidone Hydrochloride Tablets were first developed by Sunovion Pharmaceuticals Inc. and launched in the U.S. in October 2010, with domestic approval for import in January 2019 [1] - Other companies that have obtained registration for Lurasidone Hydrochloride Tablets in China include Jiangsu Hengrui Medicine Co., Ltd., Chengdu Kanghong Pharmaceutical Group Co., Ltd., and Zhejiang Hisun Pharmaceutical Co., Ltd. [1] - The domestic market sales for Lurasidone Hydrochloride Tablets are projected to be approximately RMB 52 million in the first half of 2025 [1]